<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01662232</url>
  </required_header>
  <id_info>
    <org_study_id>Char-EGCG-FMD</org_study_id>
    <nct_id>NCT01662232</nct_id>
  </id_info>
  <brief_title>Improvement of Endothelial Function by EGCG</brief_title>
  <official_title>The Role of EGCG in Different Application Forms on Flow-mediated Dilation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases are a major cause of morbidity and mortality worldwide. Impaired
      endothelial function (assessed as flow-mediated dilation) represents an early marker for
      later cardiovascular events. Epidemiological and experimental studies suggest that
      consumption of tea is associated with lower progression of atherosclerosis and reduced
      cardiovascular mortality.

      Tea contains high amounts of polyphenols with important biological activities. The green tea
      catechin epigallocatechin-3-gallate (EGCG) is the most potent physiologically active compound
      in vitro. However, little is known about its contribution to beneficial effects of tea in
      vivo.

      In this crossover study the impact of a single dose of EGCG applied in different forms (green
      tea beverage, green tea extract and EGCG) on flow-mediated dilation is investigated in
      healthy volunteers two hours after ingestion. The amount of EGCG (200 mg) corresponds to
      appr. 0.5 L of green tea. The results of the study will elucidate the contribution of EGCG in
      cardiovascular protective effects of green tea in vivo. The outcomes will provide insights
      about the role of EGCG in different application forms to improvements of endothelial function
      in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the arteria brachialis</measure>
    <time_frame>2 hours after ingestion</time_frame>
    <description>Change in flow-mediated dilation (in %) of the arteria brachialis after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG is assessed by vascular ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agonist-induced platelet aggregation in vitro</measure>
    <time_frame>2 hours after ingestion</time_frame>
    <description>Blood is drawn two hours after consumption and the effects on in vitro agonist-induced platelet aggregation after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of plasma tea polyphenol levels</measure>
    <time_frame>2 hours after ingestion</time_frame>
    <description>Blood is drawn two hours after consumption and plasma concentrations of tea polyphenols are measured after a single dose of 200 mg EGCG either as green tea beverage, green tea extract or EGCG by HPLC.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Green tea beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg EGCG as green tea beverage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Green tea extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg EGCG as green tea extract and same volume water as for tea beverage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epigallocatechin-3-gallate (EGCG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg EGCG and same volume water as for tea beverage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Water)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same volume water as for all intervention arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea beverage</intervention_name>
    <arm_group_label>Green tea beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea extract</intervention_name>
    <arm_group_label>Green tea extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EGCG</intervention_name>
    <arm_group_label>Epigallocatechin-3-gallate (EGCG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (Water)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male healthy volunteers

          -  20-50 years

          -  BMI &lt; 27 kg/m2

          -  Cholesterol &lt; 240 mg/dl

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Hypertension

          -  Conditions with impaired endothelial function

          -  Smoking

          -  Regular drug use

          -  Alcohol abuse

          -  Regular tea drinkers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Lorenz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Angiology, Campus Mitte, Charité University Medicine Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology and Angiology, Campus Mitte, Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2012</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Mario Lorenz, PhD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Green tea</keyword>
  <keyword>EGCG</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Flow-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

